- Home
- NBIX vs GMAB Comparison
NBIX vs GMAB Comparison
Compare NBIX & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- GMAB
- Stock Information
- Founded
- NBIX 1992
- GMAB 1999
- Country
- NBIX United States
- GMAB Denmark
- Employees
- NBIX N/A
- GMAB N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- NBIX Health Care
- GMAB Health Care
- Exchange
- NBIX Nasdaq
- GMAB Nasdaq
- Market Cap
- NBIX 12.0B
- GMAB 12.8B
- IPO Year
- NBIX 1996
- GMAB N/A
- Fundamental
- Price
- NBIX $123.02
- GMAB $20.95
- Analyst Decision
- NBIX Strong Buy
- GMAB Buy
- Analyst Count
- NBIX 20
- GMAB 9
- Target Price
- NBIX $163.20
- GMAB $39.17
- AVG Volume (30 Days)
- NBIX 1.6M
- GMAB 1.5M
- Earning Date
- NBIX 05-05-2025
- GMAB 05-08-2025
- Dividend Yield
- NBIX N/A
- GMAB N/A
- EPS Growth
- NBIX N/A
- GMAB 276.13
- EPS
- NBIX 2.96
- GMAB 18.36
- Revenue
- NBIX $2,412,600,000.00
- GMAB $3,230,902,140.00
- Revenue This Year
- NBIX $15.99
- GMAB $17.69
- Revenue Next Year
- NBIX $14.93
- GMAB $14.81
- P/E Ratio
- NBIX $41.60
- GMAB $11.30
- Revenue Growth
- NBIX 21.73
- GMAB 25.21
- 52 Week Low
- NBIX $84.23
- GMAB $17.24
- 52 Week High
- NBIX $157.98
- GMAB $28.96
- Technical
- Relative Strength Index (RSI)
- NBIX 62.85
- GMAB 55.72
- Support Level
- NBIX $117.59
- GMAB $20.73
- Resistance Level
- NBIX $125.63
- GMAB $21.42
- Average True Range (ATR)
- NBIX 2.98
- GMAB 0.45
- MACD
- NBIX -0.02
- GMAB 0.11
- Stochastic Oscillator
- NBIX 72.90
- GMAB 81.62
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.